Form 4: Celularity Director Ling Acquires Shares & Options

Celularity Inc. Director Geoffrey Ling, M.D., acquired 125,000 restricted stock units and 156,250 stock options under the company's 2021 Equity Incentive Plan.

Summary

• Director Geoffrey Ling, M.D., acquired 125,000 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on December 29, 2025.
• These RSUs were granted under the Celularity Inc. 2021 Equity Incentive Plan at a price of $0.00 per share.
• The RSUs will vest on the earlier of the one-year anniversary of the grant date (December 29, 2025) or the next annual stockholder meeting, contingent on Dr. Ling's continuous service.
• Following this transaction, Dr. Ling beneficially owns 236,795 shares of Class A Common Stock.
• Dr. Ling also acquired 156,250 stock options with an exercise price of $1.2 per share on December 29, 2025.
• These stock options were granted under the 2021 Plan and will vest under the same conditions as the RSUs.
• The stock options have an expiration date of December 29, 2035.
• Following this transaction, Dr. Ling beneficially owns 1,490,996 stock options.

Sentiment

Score: 7

Explanation: The filing reports a routine insider acquisition of equity as part of a compensation plan, which is generally a neutral to slightly positive signal as it aligns management incentives with shareholder interests. No negative information is present.

Positives

• An insider, Director Geoffrey Ling, M.D., increased his beneficial ownership in Celularity Inc. through the acquisition of 125,000 Restricted Stock Units (RSUs) and 156,250 stock options.
• The grants align management incentives with shareholder interests, as vesting is contingent on continuous service.

Future Outlook

The vesting schedule for the granted Restricted Stock Units and stock options indicates a future commitment from Director Ling, aligning his incentives with the company's long-term performance, contingent on his continuous service through the one-year anniversary of the grant date or the next annual stockholder meeting.

Industry Context

This filing reflects a standard practice in the biotechnology and pharmaceutical industry where executive and director compensation often includes equity-based incentives like RSUs and stock options to attract and retain talent, and to align their interests with long-term shareholder value creation. Such grants are common for companies like Celularity Inc., which operate in a capital-intensive and research-driven sector.

Comparison to Industry Standards

• Equity grants to directors, such as the 125,000 RSUs and 156,250 stock options reported, are a common component of compensation packages in the biotech sector.
• Companies like Moderna (MRNA), BioNTech (BNTX), and Regeneron Pharmaceuticals (REGN) frequently utilize similar equity incentive plans to compensate their leadership, aligning their interests with long-term company performance and shareholder value.
• The vesting conditions tied to continuous service are also standard practice across the industry to ensure retention and commitment.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants align the director's interests with long-term shareholder value.
• Employees: The existence of an equity incentive plan suggests similar opportunities may be available to other key employees, potentially boosting morale and retention.

Next Steps

• The RSUs and stock options will vest on the earlier of December 29, 2026 (one-year anniversary of grant) or the next annual stockholder meeting, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director as part of their compensation package. While insider ownership alignment is generally positive, this specific transaction does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's an expected event within the framework of an existing equity incentive plan.

Keywords

Celularity Inc., CELU, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Incentive Plan, Director Compensation, Beneficial Ownership